NCT04007094View on ClinicalTrials.gov

Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery

NATerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

January 21, 2022

Study Completion Date

January 21, 2022

Conditions
Degenerative Disc DiseaseSpinal StenosisSpondylosisSpondylolisthesis
Interventions
OTHER

ViviGen Cellular Bone Matrix

ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10

Trial Locations (1)

43201

Ohio State University, Columbus

Sponsors

Collaborators (1)

DePuy Synthes
All Listed Sponsors
collaborator

DePuy Synthes

INDUSTRY

lead

Ohio State University

OTHER

NCT04007094 - Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery | Biotech Hunter | Biotech Hunter